Cargando…
Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19
SARS-CoV-2 is responsible for the 2019 coronavirus disease (COVID-19), a global pandemic that began in March 2020 and is currently in progress. To date, COVID-19 has caused about 935,000 deaths in more than 200 countries. The respiratory system is most affected by injuries caused by COVID-19, but ot...
Autores principales: | Vitiello, A., Ferrara, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521881/ https://www.ncbi.nlm.nih.gov/pubmed/32991879 http://dx.doi.org/10.1016/j.lfs.2020.118510 |
Ejemplares similares
-
Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment
por: Vitiello, Antonio, et al.
Publicado: (2021) -
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19
por: Vitiello, Antonio, et al.
Publicado: (2021) -
Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2021) -
The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced
por: Vitiello, Antonio, et al.
Publicado: (2021) -
Pregnancy and COVID-19, focus on vaccine and pharmacological treatment
por: Vitiello, Antonio, et al.
Publicado: (2022)